AUGUST - 202319TECH OUTLOOKEastman's commitment to excellence, stability, and innovation sets it apart. The strong focus on high-quality products has earned Eastman the prestigious Malcolm Baldrige National Quality Award (MBNQA). Its century-old operations offer a reliable manufacturing process, ensuring minimal disruptions in the supply of products--a critical concern for the pharmaceutical industry.One of Eastman's groundbreaking products is BioSustane, an excipient designed to address the growing need for improved water solubility in active pharmaceutical ingredients (APIs). Many new molecular entities (NMEs) demonstrate promising therapeutic potential but suffer from poor solubility, preventing them from achieving the desired effects once inside the human body. The novel excipient tackles this issue head-on.BioSustane holds immense potential for enhancing drug effectiveness and increasing patient compliance. Eastman's extended-release excipients ensure consistent therapeutic effects while reducing the frequency of drug administration. This innovation significantly benefits patients with chronic conditions such as diabetes or cardiovascular disease by improving treatment adherence and effectiveness.Likewise, Eastman has several excipients in its portfolio to enable amorphous solid dispersion (ASD) a key technology to overcome the poor solubility challenges faced while producing new drug compounds. BioSustane's abuse-deterrent property deters misuse and encourages responsible prescribing practices by incorporating abuse deterrent characteristics into the dosage form. BioSustane promises a safer and more effective future for patients worldwide as it contributes to advancements in drug therapy.The capabilities of Eastman's BioSustane have already demonstrated its potential by helping a customer create a non-opioid dosage form effective for 72 hours, making it a unique offering in the market for postoperative pain relief."BioSustane is rather a new excipient, but it has already enabled a non-opioid pain management drug. Abuse of prescription drugs, including opioid is a significant problem for human health and for the society. There is a big need for non-opioid pain management drugs. We are very pleased that our innovation has already helped develop a non-opioid pain management drug" adds Raj Arunagiri.In addition to product innovation, Eastman strongly emphasizes customer relationships and feedback. It understands that a holistic approach is necessary for success in the pharmaceutical industry. To that end, Eastman offers formulation services along with ingredients, ensuring customers receive the support they need to bring life-changing therapies to market.Eastman's portfolio extends to solutions like cellulose esters for various pharmaceutical needs, including taste masking, film coating, and solubility enhancement.Collaboration with customers is pivotal in Eastman's growth and success. Through close communication with formulation scientists, it continually iterates and conducts new experiments to address their concerns. This customer-centric approach of continual refining enables Eastman to develop product and solution offerings tailored to the needs of the pharmaceutical industry.Eastman stands out as a leader in the pharmaceutical industry, constantly driving innovation, prioritizing customer needs, and persevering in its mission to revolutionize modern medicine and improve global health. With Eastman at the forefront of innovation, the future of medicine looks bright. We help drug formulation scientists tackle some of the persistent and prevalent formulation problems. Poorly water-soluble API is one of the significant problems facing drug delivery and Eastman is right in the middle of addressing the problem in novel ways
< Page 9 | Page 11 >